Evandro de Azambuja/congressooncologia.com.br
Jan 29, 2025, 10:11
Evandro de Azambuja: The prognostic value of residual disease RD biology and gene expression after NAT in HER2-positive EBC
Evandro de Azambuja, BSMO President 2023-2026, shared on LinkedIn:
“Our paper highlighting the prognostic value of residual disease (RD) biology and gene expression after NAT in patients with HER2-positive EBC – intrinsic subtypes at baseline provide more prognostic information while immune gene expression signatures provide more prognostic information in RD.”
Authors: A. Fernandez-Martinez, M. Tanioka, S.G. Ahn, P. Zagami, T. Pascual, M. Rediti, G. Tang, K.A. Hoadley, D. Venet, N.U. Rashid, P.A. Spears, S. Di Cosimo, E. de Azambuja, A. Choudhury, P. Rastogi, M.N. Islam, J. Cortes, A. Llombart-Cussac, S.M. Swain, C. Sotiriou, A. Prat, C.M. Perou,
A. Choudhury
A. Fernandez-Martinez
A. Llombart-Cussac
A. Prat
C. Sotiriou
C.M. Perou
cancer
D. Venet
E. de Azambuja
Evandro de Azambuja
G. Tang
J. Cortes
K.A. Hoadley
L.A. Carey
M. Rediti
M. Tanioka
M.N. Islam
N.U. Rashid
OncoDaily
Oncology
P. Rastogi
P. Zagami
P.A. Spears
S. Di Cosimo
S.G. Ahn
S.M. Swain
T. Pascual
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jan 29, 2025, 10:09
Jan 29, 2025, 10:07
Jan 29, 2025, 10:06
Jan 29, 2025, 10:06
Jan 29, 2025, 10:00